Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> MutationFrank J. Accurso, Bonnie W. Ramsey, Jordan Dunitz et al.|New England Journal of Medicine|2010Cited by 802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutationJohn P. Clancy, Michael W. Konstan, Steven M. Rowe et al.|Thorax|2011Cited by 496